Table 1. Effects of changes in activity of ADPr regulators or binders on response to PARPi.

Gene	Change	Effect	Clinical value	References
PARG	Loss of protein activity	Resistance	Can be targeted through ARH3 inhibition	(Gogola et al. [179]), (Gomez et al. [166])
ARH3	Loss of protein activity	Resistance	Can be targeted through PARGi inhibition	(Prokhorova et al. [71]), (Prokhorova et al. [35]), (Ipsen et al. [164])
PARP1	Loss or mutations of sites	Resistance	-	(Pettitt et al. [163]), (Ipsen et al. [164])
PARP2	Loss	Resistance	-	(Blessing et al. [165])
ALC1	Overexpression	Resistance	Possible marker	(Juhasz et al. [160])
HPF1	Loss	Sensitivity	Possible marker	(Gibbs-Seymour et al. [67]), (Prokhorova et al. [35])
ARH3	Overexpression	Sensitivity	Possible marker	(Prokhorova et al. [71])
ALC1	Loss of protein activity	Sensitivity	Possible marker	(Juhasz et al. [160]), (Hewitt et al. [114]), (Verma et al. [159])
XRCC1	Loss of protein activity	Sensitivity	Possible marker	(Demin et al. [180])